Amoxicillin-Clavulanate: Oral

C difficile risk
Oral Bioavailability


Defined criteria for use and/or important safety considerations. See below for more information.

  • Dosed by amoxicillin component

  • Do not use 875 mg tablet for 250 or 500 mg dose

875 mg PO q12h

CrCl > 30 mL/minCrCl 10 - 30 mL/minCrCl < 10 mL/minNo renal adjustment required500 mg PO q12h500 mg PO q24h

500 mg PO q24h

  • Give dose after dialysis on HD days

No data, consider 250 mg PO q12h

No data, consider 500 mg PO q12h

General Information

  • Primary: Polymicrobial infections with no other oral therapeutic options either alone or in combination

  • Infections with microorganisms resistant to first line agents.

  • Bite prophylaxis (when indicated) or bite infections.

For prolonged therapy, monitor liver enzymes and function.

  • Cytopenias

  • Diarrhea (less likely with twice daily dosing regimen)

  • C. difficile

  • Hepatotoxicity due to clavulanate - usually mild, liver failure is very rare.

Increased risk of rash with allopurinol

amoxicillin-clavulanate: 875-125 mg, 500-125 mg, and 250-125 mg tablets

Antimicrobial class: Aminopenicillin + Beta-lactamase inhibitor

Pregnancy category: B

Average serum half life: 1 hour

Biliary penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

CSF penetration: Insufficient data

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.